Drug Metabolism (DMET)Standardize your drug metabolism studies As a CLIA certified, GLP compiant facility utilizing the Affymetrix DMET™ microarray, SeqWright provides cost-effective analysis services for pharmacogenetic markers used in drug metabolism studies. The DMET array enables us to help you standardize your drug metabolism studies and rapidly discover genetic variations associated with drug response compared to traditional methods. The DMET array features markers in all FDA-validated genes and covers more than 90 percent of the current ADME Core markers as defined by the PharmaADME group. |
||
Key Benefits
Key Features
SeqWright's DMET array service provides coverage of a wide range of genetic variations, including common and rare SNPs, insertions, deletions, tri-alleles, and copy number—many of which are not assayed by conventional SNP methods. Unlike other SNP detection methods which interrogate markers with an average minor allele frequency (MAF) of approximately 20 percent, the ADME Core markers in the DMET array have allelic frequencies below 9 percent, although more common genetic variants are also present. SeqWright's DMET array service applications:
|
||
|